Marica Garziera
Overview
Explore the profile of Marica Garziera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scarabel L, Garziera M, Fortuna S, Asaro F, Toffoli G, Geremia S
Sci Rep
. 2020 May;
10(1):8773.
PMID: 32471996
We here explore the soluble Human Leukocyte Antigen-G (sHLA-G) expression level as clinical biomarker in metastatic colorectal cancer (mCRC). To this aim the sHLA-G protein was measured in plasma samples...
2.
Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, et al.
Gynecol Oncol
. 2019 Nov;
156(1):233-242.
PMID: 31711657
Objective: Epithelial ovarian cancer (EOC) is usually diagnosed at advanced stages with highly variable clinical outcomes, even among patients with similar clinical characteristics and treatments. Host immune system plays a...
3.
Garziera M, Cecchin E, Giorda G, Sorio R, Scalone S, De Mattia E, et al.
Cells
. 2019 Oct;
8(10).
PMID: 31581548
Carboplatin/paclitaxel is the reference regimen in the treatment of advanced high-grade serous ovarian cancer (HGSOC) in neo-adjuvant chemotherapy (NACT) before interval debulking surgery (IDS). To identify new genetic markers of...
4.
Garziera M, Roncato R, Montico M, De Mattia E, Gagno S, Poletto E, et al.
Cells
. 2019 Jun;
8(6).
PMID: 31197119
Next-generation sequencing (NGS) technology has advanced knowledge of the genomic landscape of ovarian cancer, leading to an innovative molecular classification of the disease. However, patient survival and response to platinum-based...
5.
Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Dalle Fratte C, et al.
Clin Pharmacol Ther
. 2018 Oct;
105(4):994-1002.
PMID: 30339275
Lack of information on the clinical utility of preemptive DPYD screening before fluoropyrimidine treatment is a major barrier preventing its use in clinical practice. This study aimed to define the...
6.
Garziera M, Cecchin E, Canzonieri V, Sorio R, Giorda G, Scalone S, et al.
Int J Mol Sci
. 2018 May;
19(5).
PMID: 29783665
Somatic mutations in are a hallmark of high-grade serous ovarian cancer (HGSOC), although their prognostic and predictive value as markers is not well defined. Next-generation sequencing (NGS) can identify novel...
7.
Farra R, Musiani F, Perrone F, Cemazar M, Kamensek U, Tonon F, et al.
Molecules
. 2018 Mar;
23(4).
PMID: 29597300
Despite the advances in anticancer therapies, their effectiveness for many human tumors is still far from being optimal. Significant improvements in treatment efficacy can come from the enhancement of drug...
8.
Garziera M, Scarabel L, Toffoli G
J Immunol Res
. 2017 Aug;
2017:4587520.
PMID: 28781970
The human leukocyte antigen-G (HLA-G) is considered an immune checkpoint molecule involved in tumor immune evasion. Hypoxia and the metabolic sensor hypoxia-inducible factor 1 (HIF-1) are hallmarks of metastasization, angiogenesis,...
9.
Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, et al.
Int J Mol Sci
. 2017 Jun;
18(7).
PMID: 28653974
Polymorphisms in drug-metabolizing enzymes might not completely explain inter-individual differences in toxicity profiles of patients with colorectal cancer (CRC) that receive folinic acid/5-fluorouracil/oxaliplatin (FOLFOX4). Recent data indicate that the immune...
10.
Scarabel L, Perrone F, Garziera M, Farra R, Grassi M, Musiani F, et al.
Expert Opin Drug Deliv
. 2017 Mar;
14(6):797-810.
PMID: 28266887
hepatocellular carcinoma (hcc) is the predominant form of primary liver cancer and the second leading cause of cancer-associated mortality worldwide. available therapies for hcc have limited efficacy due to often...